With the increased use of anti-TNF therapy for both ulcerative colitis and Crohn’s disease, there is serious concern about long term adverse events, especially malignancy. Recent data suggests that anti-TNF agents increase the risk of non-Hodgkin’s lymphoma; however, there is limited evidence on the risk of solid tumors. Many patients have been exposed to other immunosuppressive therapies in the past making it difficult to discern the true risk of malignancy with TNF-alpha inhibitors alone. The purpose of this review is to discuss the risk of extra-intestinal solid cancer, excluding skin cancer, in adult inflammatory bowel disease patients exposed to anti-TNF agents.
Article first published online 9 January 2013
*Beth Israel Medical Center, New York, New York
†Mount Sinai Medical Center, New York, New York.
Reprints: David Hudesman, MD, 1385 York Ave., Apt. 26C, New York, NY 10021 (e-mail: firstname.lastname@example.org).
Received April 30, 2012
Accepted May 23, 2012